NCT03132922 - MAGE-A4ᶜ¹º³²T for Multi-Tumor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 15, 2017

Primary Completion Date

December 27, 2022

Study Completion Date

September 30, 2032

Conditions

Urinary Bladder CancerMelanomaHead and Neck CancerOvarian CancerNon-Small Cell Lung CancerEsophageal CancerGastric CancerSynovial SarcomaMyxoid Round Cell LiposarcomaGastroesophageal Junction

Interventions

GENETIC

Autologous genetically modified MAGE-A4ᶜ¹º³²T cells

Infusion of autologous genetically modified MAGE-A4ᶜ¹º³²T on Day 1

RADIATION

Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation

Up to 10 subjects will be considered for Radiation sub-study. Radiation with an intensity of 1.4Gy for 5 days before infusion of MAGE-A4c1032T cells

Trial Locations (11)

14263

Roswell Park Cancer Institute, Buffalo

19111

Fox Chase Cancer Center, Philadelphia

27710

Duke University Medical Center, Duke Cancer Institute, Durham

33136

University of Miami, Miami

33612

Moffitt Cancer Center, Tampa

37203

Tennessee Oncology - Sarah Cannon Research Institute, Nashville

43210

Ohio State University Wexner Medical Center, Columbus

63110

Washington University School of Medicine, St Louis

63112

Washington University, St Louis

77030

M.D. Anderson Cancer Center, Houston

M5G1X6

Princess Margaret Cancer Centre, Toronto